Daryl Humes

Daryl Humes has a strong background in scientific research and has held various roles throughout their career. Daryl worked as an Undergraduate Research Assistant at McKerlie Lab - Hospital for Sick Children in 2003-2004 and at Michigan State University in 2004-2005. Daryl then pursued their graduate studies as a Graduate Student in the Molecular and Cellular Biology Program at Fred Hutchinson Cancer Research Center from 2006 to 2012, where they focused on identifying and characterizing mutant and circulating HIV-1 envelope proteins for use in macaque models of HIV-1 vaccine efficacy. Daryl also determined CD4 residues limiting HIV-1 infection of macaque cells during this time.

Following their graduate studies, Daryl worked as a Post-doctoral Researcher at the University of Copenhagen from 2012 to 2016, specifically in the Copenhagen Hepatitis C Program. During this time, they carried out research related to hepatitis C.

In 2016, Daryl joined Fred Hutch as a Staff Scientist, primarily focusing on lentiviral vector design and production for gene editing and transgene expression in primary T cells. Daryl also developed assays to characterize lentiviral vector titers and gene expression, as well as validated CRISPR-Cas9 mediated gene knockouts in primary CD4+ T cells.

Daryl then moved on to work at Sana Biotechnology, Inc. as a Senior Scientist from 2021 to 2022.

Currently, Daryl holds the position of Principal Scientist - Vectorology at Tr1X, starting in November 2022. Overall, their work experience demonstrates their expertise in vector development, gene editing, and virology research.

Daryl Humes completed a Bachelor of Science (BSc) degree in Biology and Bioinformatics from the University of Waterloo, which they attended from 2001 to 2006. Daryl then pursued further education and obtained a Doctor of Philosophy (PhD) degree in Molecular and Cellular Biology from the University of Washington, where they studied from 2006 to 2012.